LY20-02

Main Content

Outcomes of allogeneic transplants in patients with hodgkin lymphoma in the era of checkpoint inhibitors: A joint CIBMTR and EBMT analysis.

Study #: LY20-02

Study Status: Published

Presentation(s)

2022, EBMT (Oral)

Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: A joint CIBMTR and EBMT analysis.

Citation

Perales MA, Awan FT, Boumendil A, Patel J, Castagna L, Angelucci E, Finel H, Kulagin A, Glass B, Corradini P, Herrera AF, Blaise D, Kharfan-Dabaja MA, Halahleh K, Ahmed S, Martinez C, Giebel S, Montoto S, Jones RJ, Ahmed N, Lynch RC, de Lima MJ, Shadman M, Sauter CS, Ahn KW, Hamadani M, Bazarbachi A, Sureda A.

Blood. 2025, Aug 21: 146(8): 146(8):1011-1029. doi: 10.1182/blood.2024027197. Epub 2025, Jul 07. PMCID:PMC12530899.

PubMed

PMID: 40623049

Abstract